Table 1.

Treatment history and outcome prior to combination of As₂O₃ and tamibarotene.

Phase of treatment	Drugs	Result of treatment
At initial diagnosis
First induction therapy	ATRA, Ara-C, and IDA	hCR
Post-remission therapy 1	Ara-C and MIT	hCR
Post-remission therapy 2	Ara-C and DNR	hCR
Post-remission therapy 3	Ara-C and IDA	mCR
Maintenance therapy	ATRA	Molecular relapse
At first molecular relapse
Re-induction therapy 1	Tamibarotene	hCR
Re-induction therapy 2	As2O3	hCR
Post-remission therapy 1	As2O3	hCR
Post-remission therapy 2	As2O3	hCR
Post-remission therapy 3	high-dose Ara-C	mCR
aPBSCT	Bu and MEL	mCR
At second molecular relapse
Re-induction therapy	Tamibarotene	Hematological relapse

ATRA: all-trans retinoic acid, Ara-C: cytarabine, IDA: idarubicin, hCR: hematological complete remission, MIT: mitoxantrone, DNR: daunorubicin, mCR: molecular complete remission, aPBSCT: autologous peripheral blood stem cell transplantation, Bu: busulfan, MEL: melphalan.